scholarly journals Classifying Non-Small Cell Lung Cancer by Status of Programmed Cell Death Ligand 1 and Tumor-Infiltrating Lymphocytes on Tumor Cells

2018 ◽  
Vol 9 (1) ◽  
pp. 129-134 ◽  
Author(s):  
Shaohua Cui ◽  
Lili Dong ◽  
Jialin Qian ◽  
Lin Ye ◽  
Liyan Jiang
Keyword(s):  
Lung Cancer ◽  
Cell Death ◽  
Programmed Cell Death ◽  
Small Cell Lung Cancer ◽  
Tumor Cells ◽  
Cell Lung Cancer ◽  
Tumor Infiltrating Lymphocytes ◽  
Small Cell ◽  
Small Cell Lung ◽  
Infiltrating Lymphocytes

Correlation of β-catenin expression in non-small cell lung cancer to prognosis and CD8 positive cells infiltration.

2018 ◽  
Vol 36 (5_suppl) ◽  
pp. 142-142
Author(s):  
Satoshi Muto ◽  
Yuki Ozaki ◽  
Takuya Inoue ◽  
Takumi Yamaura ◽  
Mitsuro Fukuhara ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Small Cell Lung Cancer ◽  
Tumor Cells ◽  
Cell Lung Cancer ◽  
Progression Free Survival ◽  
Tumor Infiltrating Lymphocytes ◽  
Small Cell ◽  
Rank Test ◽  
Small Cell Lung ◽  
Infiltrating Lymphocytes

142 Background: It was reported that β-catenin expression in tumor cells suppresses dendritic cell infiltration into tumor in mouse model of melanoma. It results in less of tumor infiltrating lymphocytes. In non-small cell lung cancer (NSCLC), it is not well understood that β-catenin is involved in cancer immunity in that context. Methods: We studied the association between β-catenin expression and CD8 positive cells infiltration in NSCLC. Ninety-one patients with NSCLC who had complete surgical resection during January 2013 to June 2015 were subjected. β-catenin expression of tumor cells and CD8 positive cells infiltration were analyzed by immunohistochemistry. Survival analysis including over-all survival (OS) and progression-free survival (PFS) were also statistically examined by log-rank test. Results: Fourteen cases (15%) were β-catenin positive. Among 14 β-catenin positive cases, only 2 cases (14%) had CD8 positive cells infiltration. Seventy-five cases (97%) had CD8 positive cells infiltration in β-catenin negative tumors (p < 0.01). Squamous cell carcinoma was relatively higher level of expression than others (44% vs. 9%) and mean primary tumor size was larger in β-catenin positive tumors (3.6 cm) than those in negative tumors (2.7 cm). Median OS was 43.8 months and median PFS was 37.0 months in β-catenin positive group. They were not reached in β-catenin negative group. Both OS and PFS were shorter in β-catenin positive cases (p < 0.01). Conclusions: In NSCLC, β-catenin expression was negatively associated with CD8 positive cells infiltration and poor prognosis. We furthermore will focus on the association between β-catenin expression in tumor and clinical efficacy or resistant mechanism of immune checkpoint blockades.

Protein expression of programmed cell death ligand 1 and ligand 2 and their prognostic values in extensive-stage small cell lung cancer.

2021 ◽  
Vol 39 (15_suppl) ◽  
pp. e20593-e20593
Author(s):  
Ke (Kirsten) Zu ◽  
Jeanette Bæhr Georgsen ◽  
Peter Meldgaard ◽  
Anne Deitz ◽  
Mark Ayers ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cell Death ◽  
Programmed Cell Death ◽  
Protein Expression ◽  
Small Cell Lung Cancer ◽  
Tumor Cells ◽  
Cell Lung Cancer ◽  
Small Cell ◽  
Small Cell Lung ◽  
Extensive Stage

e20593 Background: The receptor-ligand interaction between programmed cell death protein-1 (PD-1) and its ligands (PD-L1 and PD-L2) plays a critical role in tumor immune evasion and has become a therapeutic target in a number of cancer types, including extensive stage small cell lung cancer (ES-SCLC). While there are some published data on PD-L1 expression in ES-SCLC, the results vary with different laboratory assays or thresholds of positivity employed. Data on PD-L2 expression is very limited in ES-SCLC. The prognostic values of these biomarkers are not well understood. The current study aims to address this data gap. Methods: A retrospective cohort study of patients with ES-SCLC receiving usual care in the clinical setting in Denmark was conducted. Formalin-fixed paraffin embedded (FFPE) tumor tissue samples and data on patient characteristics and clinical outcomes were obtained for the patient population. Protein expression of PD-L1 and PD-L2 was determined by immunohistochemistry (IHC), and a combined positive score (CPS, the percentage of tumor cells and mononuclear inflammatory cells expressing the biomarker at any intensity out of the total number of tumor cells) of ≥1 was used to define biomarker positivity. Kaplan-Meier plots and Cox proportional hazard models were employed to assess the relationship between PD-L1 and PD-L2 protein expression and overall survival (OS). Results: Among the 80 patients with ES-SCLC included in this study, 25 and 29 were positive for PD-L1 and PD-L2, respectively (Table). A total of 68 patients had concordant expression status of PD-L1 and PD-L2 (21 as double positive and 47 as double negative). There was a significant association between PD-L1 positivity and longer OS, which persisted after adjustment for age and stage at SCLC diagnosis, performance score, prior exposure to chemotherapy, and lactate dehydrogenase levels (Table). Similar results were observed for PD-L2 (Table), and the data did not suggest any additional prognostic value of PD-L2 expression independent of PD-L1 expression. Conclusions: PD-L1 and PD-L2 positivity was both observed, and highly correlated with each other, in approximately one third of the ES-SCLC tumor samples tested. Patients with PD-L1 or PD-L2 positive tumors have significantly longer OS than those with negative tumors in this study, independent of other known prognostic factors.[Table: see text]

Sign in / Sign up

Export Citation Format

Share Document